

Original Research

Variation in Prevalence and Burden of Chronic Obstructive Pulmonary Disease by State and Insurance Type in the United States

Carol Bazell, MD, MPH¹ Maggie Alston, CHFP¹ Norbert Feigler, MD² Hayley D. Germack, PhD, MHS, RN³
Stephanie Leary, ASA, MAAA¹ Winston Fopalan, MD, MPH¹ David Mannino, MD, FCCP, FERS⁴

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) poses a substantial burden on individuals and the U.S. health care system. Up-to-date information describing individuals with COPD and their acute hospital-based health care utilization at the state level and by insurance type is lacking.

Methods: Individuals with COPD aged 40 and older were identified from large databases of Medicare fee-for-service, Medicaid, and commercial health insurance claims, and counts were extrapolated to the U.S. health insurance market. Demographics and outcome metrics were quantified between January 1 and December 31, 2021, and summarized by state and insurance type.

Results: Approximately 11.7 million insured individuals had COPD in 2021. The largest share were covered by Medicare (79.4%), followed by commercial insurance (11.3%) and Medicaid (9.3%). COPD prevalence varied among states, ranging from 44 (Utah) to 143 (West Virginia) per 1000 insured individuals. Nationwide, annual all-cause mortality for individuals with COPD covered by Medicare (11.5%) was more than double that of Medicaid (5.1%). There were 1.8 million COPD-related acute inpatient hospitalizations nationwide, with the largest share among individuals covered by Medicare (86.4%), followed by Medicaid (9.0%) and commercial insurance (4.6%). COPD-related hospitalization rates also varied among states, ranging from 97 (Idaho) to 200 (District of Columbia) per 1000 individuals with COPD. There were 1.4 million COPD-related emergency department/observation encounters not resulting in acute inpatient admissions nationwide.

Conclusion: There is substantial state and payer variation in COPD prevalence and burden. Understanding this variation provides valuable insights into populations with unmet needs that can inform public health strategies to address gaps.

1. Milliman, Inc., New York, New York, United States
2. US Medical Respiratory, BioPharmaceuticals, AstraZeneca, Wilmington, Delaware, United States
3. US Medical Evidence, BioPharmaceuticals, AstraZeneca, Wilmington, Delaware, United States
4. COPD Foundation, Miami, Florida, United States

Abbreviations:

AHA=American Hospital Association; **BRFSS**=Behavioral Risk Factor Surveillance System; **C**=commercial; **CMS**=Centers for Medicare & Medicaid Services; **COPD**=chronic obstructive pulmonary disease; **ED**=emergency department; **ED/Obs**=emergency department/observation; **FFS**=fee-for-service; **GOLD**=Global initiative for chronic Obstructive Lung Disease; **HCG**=Milliman Consolidated Health Cost Guidelines™; **HCPCS**=Healthcare Common Procedure Coding System; **HCUP**=Healthcare Cost and Utilization Project; **ICD-10-CM**=International Classification of Diseases, Tenth Revision, Clinical Modification; **LABA**=long-acting beta2-agonist; **LAMA**=long-acting muscarinic antagonist; **MC**=Medicare; **MD**=Medicaid; **T-MSIS**=Transformed Medicaid Statistical Information System

Funding Support:

This study was funded by AstraZeneca Pharmaceuticals LP (Wilmington, Delaware). Milliman, Inc., received consulting fees from AstraZeneca

Pharmaceuticals LP to conduct the research and provide editorial support for the manuscript.

Citation:

Bazell C, Alston M, Feigler N, et al. Variation in prevalence and burden of chronic obstructive pulmonary disease by state and insurance type in the United States. *Chronic Obstr Pulm Dis*. 2025;12(2):158-174. doi: <https://doi.org/10.15326/jcopdf.2024.0560>

Publication Dates:

Date of Acceptance: February 26, 2025

Published Online Date: ???

Address correspondence to:

Winston Fopalan, MD, MPH
Milliman, Inc.
New York, NY
Email: winston.fopalan@milliman.com
Phone: (646) 473-3230

Keywords:

COPD; prevalence; demographics; hospitalizations; health insurance

This article has an online supplement.

Introduction

Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms caused by abnormalities of the airways and alveoli that result in persistent, often progressive, airflow obstruction.¹ This condition poses a significant challenge to the individuals living with COPD and the health care system due to its prevalence, impact on health and quality of life, and contribution to mortality. Chronic lower respiratory disease (including COPD) was the sixth leading cause of death² in the United States in 2018–2021, and 10.1% of adults aged 45 and older have COPD based on 2021 Behavioral Risk Factor Surveillance System (BRFSS) survey data.³ State-level prevalence varies substantially, with the highest rate seen in West Virginia (17.3%) and the lowest reported in Hawaii (6.0%).³

Known risk factors for developing COPD include environmental exposures such as: tobacco smoking⁴; inhalation of toxic particles and gases from household⁵ and outdoor air pollution⁶; occupational exposures such as pesticides⁷ and burn pits⁸; infections such as human immunodeficiency virus infection⁹ and tuberculosis¹⁰; other medical conditions such as asthma¹¹; and increasing age.¹² Furthermore, low socioeconomic status is associated with an elevated lifetime risk of developing COPD.¹³

COPD poses a substantial burden on individuals with COPD and the health care system,^{14,15} with direct costs generally increasing with COPD severity and exacerbation frequency.¹⁶ Acute hospital-based health care utilization related to COPD is not uniformly distributed nationwide, and previous analysis found wide variation in COPD hospitalizations and emergency department (ED) visits among states.³

While there is recent information on COPD prevalence at the national and state levels from survey data and COPD-related acute hospital-based utilization from public health tracking sources, there is no current, comprehensive information available describing individuals living with COPD and their hospital-based health care utilization at the state level and by type of insurance coverage. Health insurance coverage in the United States falls under 2 main categories: public coverage (provided by the Medicare and Medicaid programs) and private coverage or commercial insurance (e.g., employment-based and direct purchase insurance plans).¹⁷ Medicare provides health insurance for individuals aged 65 years or older and individuals under 65 with certain medical conditions or disabilities¹⁸; and Medicaid provides health insurance for eligible children, pregnant women, adults with limited income, and elderly or disabled adults.¹⁹

Because states design and administer their own Medicaid programs within federal rules²⁰ and differ in their decisions on the Affordable Care Act's expansion of Medicaid coverage,²¹ the characteristics and health of the Medicaid-insured population differ substantially by state. In contrast, Medicare has nationally consistent eligibility criteria that result in more similar populations of Medicare-insured individuals across states. Commercial insurance is primarily provided through employment but the availability of payers operating across local individual health insurance exchanges varies, which can result in heterogeneous commercial insurance enrollment across states.²²

The varying health insurance eligibility requirements and resulting mix of insurance coverages across states have potential implications for COPD prevalence and COPD-related acute hospital-based utilization identified from administrative claims. For example, smoking tobacco is a well-established risk factor for COPD and COPD exacerbations.²³ Medicaid-insured individuals, who have the highest cigarette smoking rates,²⁴ also have the highest 30-day hospital readmission rates following COPD-related hospitalizations.²⁵ Additionally, the older Medicare population has both higher prevalence and complexity of COPD, based on the occurrence of claims for certain comorbid conditions, compared to the younger commercially-insured population, consistent with increasing age as a COPD risk factor.²⁶

The objective of this study is to characterize the diagnosed population with COPD and their COPD-related acute hospital-based utilization and all-cause mortality among the U.S. insured population by insurance type and state ("state" in this paper includes states, Puerto Rico, and the District of Columbia). This information may provide insights into opportunities for reducing the substantial burden of COPD on individuals and the health care system.

Methods

Study Design

This observational retrospective study used the 2019–2021 Medicare 100% Research Identifiable Files, which contain all Medicare Parts A, B, and D claims data for 100% of Medicare fee-for-service (FFS)-insured individuals; the 2019–2021 (preliminary for 2021) Transformed Medicaid Statistical Information System (T-MSIS) Analytic Files, which contain all claims data (Medicaid FFS) and encounter data (managed Medicaid) for 100% of Medicaid-insured individuals; and the 2019–2021 Milliman Consolidated Health Cost Guidelines™ (HCG) Sources Database+ Analytic Files, which contain claims data for approximately 50 million (23% of) commercially-insured individuals. Medical and pharmacy administrative claims were used to identify individuals diagnosed with COPD between January 1, 2019,

and December 31, 2021. Demographics and outcome metrics were identified from January 1, 2021, through December 31, 2021 medical and pharmacy claims.

Insured COPD Sample Populations

Insured Population

Individuals were included in the insured population samples if they met all of the following inclusion criteria in 2021: (1) had at least one month of medical and pharmacy enrollment, (2) had both medical and pharmacy coverage for each enrollment month, (3) were continuously enrolled from the first month of enrollment (i.e., no gap in coverage) through all months of coverage, and (4) were at least 40 years of age. All individuals covered by Medicare and Medicaid were included in the Medicare population and excluded from the Medicaid population. Individuals were assigned to states using mailing address locations. All references to insured individuals or the insured population throughout this paper mean individuals insured by Medicaid, Medicare, or commercial health insurance.

COPD Sample Population

Individuals in the insured population samples were identified as diagnosed with COPD if they met at least one of the following criteria between January 1, 2019, and December 31, 2021: (1) at least one acute or nonacute inpatient claim (Table B1 in the online supplement) with a COPD International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code (Table B2 in the online supplement) reported in any diagnosis code position; and (2) at least 2 qualified outpatient, emergency department (ED), observation, or urgent care claims (Table B1 in the online supplement) with a COPD ICD-10-CM diagnosis code (Table B2 in the online supplement) reported in any diagnosis code position on different dates of service at least 30 days apart.

Exclusion Criteria

Commercially-insured individuals diagnosed with COPD aged 65 or older in 2021 were excluded to avoid member duplication due to universal eligibility for age-based Medicare coverage that begins at age 65.

COPD Prevalence Estimation

See Figure A1 in the online supplement for the development of the COPD population samples for each insurance type. Due to data quality limitations, prevalence metrics for Puerto Rico and the District of Columbia for Medicaid and commercial insurance were replaced with the South Atlantic census division values.

COPD Sample Population Extrapolation

To extrapolate insured individuals with COPD from the sample populations identified in claims data to the total insured COPD populations, insurance type-specific COPD prevalence rates at the state and nationwide geographic levels were multiplied by the total insured population counts for each insurance type at the corresponding geographic levels. Total insured population counts were sourced from Centers for Medicare & Medicaid Services (CMS) data,²⁷ T-MSIS enrollment files, and the American Community Survey²⁸ and Small Area Health Insurance Estimates²⁹ data, for Medicare, Medicaid, and commercial insurance types respectively. Medicare FFS COPD prevalence rates were used to extrapolate to all of Medicare (FFS and Medicare Advantage). Outcome metric rates were determined from claims data for the COPD sample populations as rates per 1000 individuals with COPD in each insurance type and geography and multiplied by the total insured COPD population count for each insurance type and level of geography as described above.

COPD Sample Population Demographics

Sample population demographic metrics were assigned to states based on the mailing address location of individuals with COPD. Due to data quality limitations, demographic metrics for Puerto Rico and the District of Columbia for Medicaid and commercial insurance were replaced with the South Atlantic census division values.

Age

Age refers to an individual's age as of January 1, 2021, using date of birth for Medicare and Medicaid-insured populations and year of birth for the commercially-insured population.

Dual Eligibility

Medicare-insured individuals were identified as dually eligible if they had at least one month of dual-eligibility in 2021 based on the combination of monthly Medicare-Medicaid dual-eligibility code and Medicare entitlement/buy-in indicator in Medicare data.

Sample Population Outcome Metrics

Sample population outcome metrics were assigned to states based on the mailing address location of individuals with COPD who experienced the outcomes. The number of COPD-related hospitalizations and 30-day readmissions in Medicare, Medicaid, and commercial claims data were extrapolated to the total hospitalization and readmission counts using the same methodology described in the COPD

Sample Population Extrapolation section. Due to data quality limitations, the same adjustments described in the COPD Sample Population Extrapolation section were applied. Additionally, the commercial insurance readmission rate for Montana was replaced with the Mountain census division value due to low sample size.

All-Cause Mortality

All-cause mortality was identified for individuals with COPD who had a date of death from any cause in 2021. Mortality information was only available for Medicare- and Medicaid-insured individuals.

COPD-Related Acute Hospital-Based Utilization

COPD-related acute hospital-based utilization was defined as hospital-based utilization (inpatient hospitalizations and emergency department/observation encounters) that met at least one of the following criteria: (1) a principal diagnosis code of COPD (Table B2 in the online supplement); (2) a principal diagnosis code of an acute pulmonary condition, sepsis, or respiratory failure (Table B3 in the online supplement), and a secondary diagnosis code of COPD unless the principal diagnosis code was for select acute pulmonary conditions commonly diagnosed in the setting of COPD exacerbations, such as acute bronchitis and unspecified pneumonia (Table B3 in the online supplement); or (3) a specific diagnosis code for COPD or bronchiectasis with acute lower respiratory infection or acute exacerbation in any diagnosis code position (acute exacerbations in Tables B2 and B3 in the online supplement).

COPD-Related Acute Inpatient Hospitalizations

COPD-related acute inpatient hospitalizations were identified from acute inpatient hospital facility claims that met the COPD-related acute hospital-based utilization definition above. Acute inpatient facility claims were identified from specific claim files (Medicare, Medicaid), provider numbers (Medicare), and claims characteristics, including bill types and revenue codes (Medicaid, commercial).

COPD-Related Emergency Department/Observation Encounters

COPD-related emergency department/observation (ED/Obs) encounters were identified from outpatient facility claims for emergency department and observation encounters at a hospital that met the COPD-related acute hospital-based utilization definition above but which did not result in an acute inpatient admission to that hospital.

Outpatient facility claims for ED/Obs encounters for Medicare- and commercially-insured individuals were identified from specific claim files, bill types, provider

specialty codes, and/or ED-specific revenue and HCPCS codes. For Medicaid-insured individuals, identification of outpatient facility claims for ED/Obs encounters for 36 states and Puerto Rico was based on CMS' recommended approach, which utilizes a combination of place-of-service, bill type, and revenue codes to identify outpatient institutional claims,³⁰ coupled with ED-specific revenue codes and ED and observation HCPCS codes. For 12 states that had data quality issues impacting at least one of the CMS methodology's characteristics for identifying outpatient facility claims, or where this standard approach resulted in noncredible values, approaches using other combinations of these characteristics were used. For Utah, Illinois, and the District of Columbia, no standard characteristics used in CMS' methodology were supported by usable data so the COPD-related ED/Obs utilization metrics were replaced with the respective census division values for each state for Medicaid.

30-day Readmission Rates Following COPD-Related Acute Inpatient Hospitalizations


Readmissions were unplanned admissions to an acute inpatient hospital that occurred within 30 days following discharge from a COPD-related acute inpatient hospitalization (index admission). Readmissions were considered "planned" and excluded if they were for certain types of care (e.g., transplant surgery) or for scheduled procedures not resulting in acute illness or complications of care.³¹ Index admissions were excluded if they met at least one of the following criteria: (1) the individual was not discharged alive, (2) the individual did not have 30 days postdischarge enrollment, or (3) the individual was discharged against medical advice. Only the first admission within 30 days of the index admission's discharge date was considered a readmission, and readmissions to the same hospital on the day of discharge and for the same condition as the index admission were considered a single admission.

Results

Prevalence and Demographic Characteristics

Figure 1 displays the prevalence and insurance type distribution of insured individuals with COPD by state. COPD prevalence was highly variable, with Utah having the lowest rate (44 per 1000 insured individuals) and West Virginia having the highest (143 per 1000 insured individuals). Across all states, Medicare covered the highest proportion of insured individuals with COPD. See Table A1 in the online supplement for prevalence and count of individuals with COPD for each insurance type and state.

Figure 2 displays the prevalence of COPD among Medicaid-insured individuals compared to the Medicaid proportion of total non-Medicare-insured individuals

Figure 1. COPD Prevalence per 1000 Insured Individuals

Note: Due to data quality limitations, demographic characteristics of Medicaid- and commercially-insured individuals in the District of Columbia and Puerto Rico were replaced with the South Atlantic census division values.


COPD=chronic obstructive pulmonary disease

(Medicaid- and commercial-insured individuals aged 40–64) in each state. While Medicaid insured a relatively low proportion of the non-Medicare-insured population aged 40–64 in non-expansion states, COPD prevalence was relatively high in Medicaid-insured individuals.

Table 1 displays demographic characteristics of insured individuals with COPD, by state and insurance type. Individuals with COPD insured by Medicare—including

those who were dually eligible for Medicaid—were the oldest with a mean age of 73 years, compared to Medicaid (55 years) and commercial (56 years). The majority of individuals with COPD were female in all states except Hawaii. All-cause mortality rates were higher among individuals with COPD insured by Medicare compared to those insured by Medicaid at 11.5% and 5.1%, respectively.

Figure 3 displays a comparison of the average age of

Figure 2. Medicaid COPD Prevalence Compared to the Medicaid Proportion of Total Non-Medicare-Insured Individuals^a

Note 1: States represented by gray circles had not adopted Medicaid expansion as of January 1, 2021.²¹

Note 2: Puerto Rico was not included in this scatterplot due to being an outlier (9.5%; 50.5%).

^aMedicaid- and commercially-insured individuals aged 40–64

COPD=chronic obstructive pulmonary disease

individuals with COPD insured by Medicare and the annual all-cause mortality rate for that population. The vertical (age) and horizontal (all-cause mortality) lines, which indicate the national average for the respective metric, divide the chart into 4 quadrants. Almost half (46.2%) of the states in the high mortality/low age quadrant had a high percentage (above the 75th percentile in the state distribution) of dually-eligible Medicare-insured individuals with COPD compared to other states with different mortality/age relationships, where all-cause mortality was consistent with or lower than age-based expectations. Among states in the high mortality/low age quadrant, all-cause mortality was higher than would generally be expected based on age. Figure A2 in the online supplement shows that all states (except Puerto Rico) had a higher percentage of individuals with COPD covered by Medicare who were dually eligible compared to the percentage of all Medicare-covered individuals who were dually-eligible.

COPD-Related Acute Inpatient Hospitalizations

Figure 4 displays the rates and insurance type distribution of COPD-related acute inpatient hospitalizations for insured individuals with COPD by state. Nationwide, there were 154 COPD-related acute inpatient hospitalizations per 1000 insured individuals with COPD. This figure shows

the variation and substantial national burden of COPD-related acute inpatient hospitalizations, with Idaho having the lowest rate (97 per 1000) and the District of Columbia having the highest (200 per 1000). Medicare covered the highest proportion (65.8%–92.5%) of COPD-related acute inpatient hospitalizations in each state except for Puerto Rico, where Medicaid's share was highest (49.6%).

Figure 5 displays the percentage of insured individuals with COPD who had at least one COPD-related acute inpatient hospitalization by insurance type and state. Nationwide and in most states, a similar percentage of Medicare-insured individuals with COPD had at least one COPD-related acute inpatient hospitalization compared to Medicaid-insured individuals (12.2% versus 12.0% nationwide). The percentage of commercially-insured individuals with COPD with at least one COPD-related acute inpatient admission (5.2% nationwide) was less than half that of Medicare-insured individuals nationwide and across most states.

Table 2 displays COPD-related acute inpatient hospitalization metrics for insured individuals with COPD by state and insurance type. Nationwide, there were approximately 1.8 million COPD-related acute inpatient hospitalizations among insured individuals in 2021, and 11.4% of insured individuals with COPD had at least one COPD-related acute inpatient hospitalization. Medicare

Table 1. Demographic Characteristics of Insured Individuals With COPD Insured Individuals With COPD


Nationwide or State	Average Age				% Female				% Dually-Eligible	Annual All-Cause Mortality Rate (%)	
	Total	MC	MD	C	Total	MC	MD	C	MC	MC	MD
Nationwide	70	73	55	56	56.1	56.3	56.9	53.7	35.2	11.5	5.1
Alabama	69	72	55	55	57.0	57.4	62.0	53.0	36.1	12.7	7.1
Alaska	68	72	56	56	52.5	53.0	50.6	51.9	46.2	11.3	3.6
Arizona	70	75	55	56	54.5	54.5	54.9	54.4	16.7	10.4	5.6
Arkansas	69	72	54	55	57.1	57.8	58.0	51.7	34.9	11.8	2.2
California	71	74	56	56	54.0	54.2	53.9	52.0	54.2	10.9	5.4
Colorado	69	73	55	56	55.3	55.5	55.6	53.0	34.0	10.7	4.9
Connecticut	71	75	56	56	56.9	57.7	55.4	51.8	45.9	12.1	3.3
Delaware	70	74	55	57	55.8	56.7	56.3	49.8	25.1	10.7	4.5
District of Columbia	64	71	55	56	58.1	58.7	58.8	54.3	75.0	13.1	6.5
Florida	72	75	56	56	57.2	57.6	57.2	54.3	30.9	12.0	8.1
Georgia	70	73	55	55	56.9	56.8	60.1	55.6	33.2	12.5	7.7
Hawaii	70	75	57	55	48.5	48.3	47.7	49.8	23.3	9.9	5.9
Idaho	70	73	56	56	53.1	52.7	58.5	53.1	33.6	10.9	6.9
Illinois	70	73	56	56	57.2	58.1	53.2	54.2	34.0	11.3	5.6
Indiana	68	72	54	56	56.6	57.0	59.5	52.7	35.2	11.8	5.2
Iowa	70	73	56	56	54.0	53.6	58.3	53.0	25.5	11.0	4.4
Kansas	71	73	56	56	56.8	56.6	61.6	55.5	25.3	11.1	7.4
Kentucky	66	71	53	55	55.7	55.1	59.0	55.4	40.9	11.7	4.6
Louisiana	68	72	54	56	57.9	57.3	62.1	56.1	46.6	12.4	5.1
Maine	69	72	54	57	53.6	53.9	53.3	51.3	57.4	11.9	5.1
Maryland	69	73	55	56	58.0	58.7	56.6	54.3	33.5	10.7	4.1
Massachusetts	70	73	56	58	55.6	56.4	52.2	52.3	39.2	10.3	5.1
Michigan	68	72	54	57	56.0	56.8	53.8	52.6	39.5	11.2	4.6
Minnesota	69	72	55	56	54.7	55.1	53.7	52.9	31.9	10.9	2.4
Mississippi	69	72	55	55	58.6	58.2	61.4	60.5	44.5	12.1	7.3
Missouri	69	72	56	56	56.6	56.3	59.5	57.1	33.6	11.4	6.5
Montana	70	73	54	57	56.6	56.2	58.0	58.9	32.9	11.4	4.6
Nebraska	71	74	56	56	55.1	55.4	59.1	52.4	23.2	11.0	6.2
Nevada	70	73	55	56	57.0	57.6	55.1	54.0	36.9	11.1	4.6
New Hampshire	70	73	56	57	56.7	57.7	53.2	52.2	28.4	10.6	5.9
New Jersey	71	75	55	57	57.5	58.2	57.9	53.1	23.0	11.8	4.7
New Mexico	71	74	55	56	54.0	54.1	53.4	54.2	34.4	11.7	5.4
New York	70	75	56	57	55.3	56.5	51.3	51.6	40.5	11.8	4.6
North Carolina	69	72	55	56	55.8	56.3	58.9	51.0	34.6	11.5	6.9
North Dakota	70	74	54	56	53.2	53.4	56.2	50.6	27.5	10.8	5.9
Ohio	67	73	55	56	55.7	55.4	59.1	54.0	29.9	11.7	3.9
Oklahoma	69	72	56	56	57.9	58.1	61.4	54.8	37.2	12.0	5.5
Oregon	69	72	55	57	55.0	55.2	55.3	52.5	42.0	10.9	5.3
Pennsylvania	69	73	55	57	55.2	55.2	58.9	52.2	29.5	11.2	4.2
Puerto Rico	70	77	55	56	58.9	59.3	58.8	54.3	9.7	7.0	6.5
Rhode Island	70	74	55	57	55.3	55.7	56.8	52.0	25.4	10.3	2.1
South Carolina	70	73	54	56	56.6	56.1	63.6	56.8	20.2	11.2	6.0
South Dakota	71	73	54	56	54.8	54.9	62.5	51.4	29.2	10.4	3.2
Tennessee	69	73	54	56	56.4	56.3	62.4	54.1	31.2	12.4	7.6
Texas	71	74	55	55	57.3	57.5	60.7	54.8	30.5	12.6	4.4
Utah	69	73	54	55	54.5	54.3	58.3	54.2	24.5	10.5	4.0
Vermont	70	72	55	57	53.9	54.6	53.2	48.4	50.9	10.8	4.8
Virginia	70	74	55	55	56.5	56.2	58.7	56.6	25.6	11.8	5.5
Washington	70	74	55	57	54.7	54.4	54.7	57.2	34.4	11.5	2.2
West Virginia	67	71	54	55	56.2	55.6	61.2	54.2	44.4	11.6	5.3
Wisconsin	69	72	54	58	54.4	54.8	54.5	51.5	39.4	11.0	4.4
Wyoming	70	73	54	56	56.9	57.1	65.6	52.5	28.2	11.4	6.9

(continued on next page)

For personal use only. Permission required for all other uses.

Note: Due to data quality limitations, demographic characteristics of Medicaid- and commercially-insured individuals in the District of Columbia and Puerto Rico were replaced with the South Atlantic census division values. COPD=chronic obstructive pulmonary disease; MC=Medicare; MD=Medicaid; C=commercial

Figure 3. Average Age Compared to Annual All-Cause Mortality for Medicare-Insured Individuals With COPD



Note: Puerto Rico was not included in this scatterplot due to being an outlier [77.1;7.0%]

COPD=chronic obstructive pulmonary disease

accounted for 86.4% of these hospitalizations, while Medicaid and commercial insurance accounted for 9.0% and 4.6%, respectively. About 20.4% of COPD-related acute inpatient hospitalizations resulted in an all-cause readmission within 30 days after discharge. Information on ED/Obs encounters for insured individuals with COPD is reported in Table A2 in the online supplement and shows 1.4 million COPD-related ED/Obs encounters among insured individuals nationwide, with rates varying among states and insurance types.


Figure 6 displays the 30-day all-cause readmission rates following COPD-related acute inpatient hospitalizations by insurance type and state. Nationwide, readmission rates were highest in Medicare (21.2%), followed by Medicaid (17.2%) and commercial insurance (10.9%). Rates showed variability across states, with Medicaid (10.6% in Rhode Island to 20.5% in Florida) and commercial insurance (4.3% in Vermont to 25% in Alaska) showing wider variation than Medicare (16.1% in Idaho to 24.1% in West Virginia).

Table 3 displays the prevalence of COPD in insured individuals and shows the relationship between COPD-related acute inpatient hospitalizations for individuals aged 40 and older and all acute inpatient hospitalizations by state.³² Nationwide, COPD-related acute inpatient hospitalizations in insured individuals aged 40 and older accounted for 4.3% of all-cause hospitalizations for all ages nationwide. This percentage varied substantially across states, with the highest percentage seen in Maine (10.0%) and the lowest in New Jersey (2.1%). No adjustments were made for differences in the prevalence of COPD, demographic characteristics of states' overall populations, Medicaid expansion experience, health care treatment patterns, or other unobserved factors.

Discussion

COPD is a major cause of morbidity and mortality in the United States, resulting in substantial disease burden that varies by state and health insurance type. Based on this analysis of administrative claims data, an estimated 11.7 million insured individuals, or 7.7% of the 40 and older U.S. population who were covered by insurance, had COPD in 2021. The annual all-cause mortality rate was 11.5% for individuals insured by Medicare and 5.1% for those insured by Medicaid. Furthermore, there were 1.8 million COPD-related acute inpatient hospitalizations in 2021, accounting for 4.3% of all acute inpatient hospitalizations in that year.

State-level COPD prevalence in this study varied widely, likely driven in part by differences in the state distribution of known risk factors for developing COPD (e.g., smoking). For example, West Virginia and Kentucky had the highest prevalence of COPD in insured individuals and the fifth-highest and highest rates, respectively, of current smoking among adults aged 45 and older in 2021.³ The state-level claims-based COPD prevalences in this study were directionally aligned with the survey-based prevalence estimates based on 2021 BRFSS data,³ although the claims-based rates were generally lower (e.g., West Virginia's COPD prevalence in this study was 14.3% compared to 17.3% in BRFSS). This is consistent with other research comparing the prevalence of chronic conditions based on self-reported data (e.g., BRFSS survey data) to administrative claims estimates. Other studies have identified substantial differences in prevalence depending on the estimation methodology, potentially due to survey interpretation

Figure 4. COPD-Related Acute Inpatient Hospitalizations Per 1000 Insured Individuals With COPD

Note: Due to data quality limitations, COPD-related acute inpatient hospitalizations for Medicaid- and commercially-insured individuals in the District of Columbia and Puerto Rico were replaced with the South Atlantic census division values.

COPD=chronic obstructive pulmonary disease


issues, selection into insurance and plan selection among insured individuals (e.g., FFS versus Medicare Advantage), and the stringency and specificity of claims-based disease identification algorithms.³³

The burden of COPD varied among populations with different insurance types and within an insurance type across geography, especially for Medicaid where eligibility criteria varied across states. While commercial insurance covered the largest share (48.8%) of individuals, only 11.3%

of individuals with COPD had commercial insurance. In contrast, Medicare's share of individuals was lower at 41.0%, while its portion of insured individuals with COPD was much higher at 79.4%. The concentration of individuals with COPD in the Medicare-insured population is consistent with increasing age as a risk factor for COPD (Medicare's average age is 73, compared to 56 in commercial insurance), as the disease can result from an accumulation of gene-environment interactions that cause persistent

For personal use only. Permission required for all other uses.

Figure 5. Percentage of Insured Individuals With COPD Who Had at Least One COPD-Related Acute Inpatient Hospitalization



Note: Due to data quality limitations, the percentages of Medicaid- and commercially-insured individuals with a COPD-related acute inpatient hospitalization in the District of Columbia and Puerto Rico were replaced with the South Atlantic census division values.

COPD=chronic obstructive pulmonary disease

For personal use only. Permission required for all other uses.

Table 2. COPD-Related Acute Inpatient Hospitalizations and 30-Day Readmission Rates for Insured Individuals With COPD

Nationwide or State	Number of COPD-Related Acute Inpatient Hospitalizations (in Thousands)				% of Individuals With COPD With a COPD-Related Acute Inpatient Hospitalizations (in Thousands)				30-Day Readmission Rate Following COPD-Related Acute Inpatient Hospitalizations (%)			
	Total	MC	MD	C	Total	MC	MD	C	Total	MC	MD	C
Nationwide	1799.0	1554.0	163.0	82.0	11.4	12.2	12.0	5.2	20.4	21.2	17.2	10.9
Alabama	40.5	36.4	2.0	2.1	12.4	13.7	12.9	5.1	19.1	19.9	17.4	7.0
Alaska	2.0	1.6	0.3	0.1	10.2	10.6	11.6	3.6	17.0	17.8	12.7	25.0
Arizona	28.2	23.2	3.7	1.4	10.5	10.7	12.3	6.1	19.2	20.2	15.5	14.3
Arkansas	20.8	18.3	1.7	0.8	11.1	11.8	13.2	4.5	22.2	23.1	19.6	7.5
California	149.5	131.1	15.0	3.5	11.1	11.5	11.0	4.7	21.4	22.0	18.5	14.8
Colorado	16.6	14.0	2.0	0.7	9.2	9.6	10.2	4.2	16.9	17.3	15.6	13.5
Connecticut	21.2	18.5	2.1	0.5	12.5	13.5	11.6	4.8	21.4	22.2	19.5	5.0
Delaware	5.8	4.9	0.6	0.3	11.5	12.2	13.1	5.4	20.5	21.6	15.6	16.7
District of Columbia	3.8	2.5	1.1	0.2	14.0	16.4	14.0	5.5	21.8	23.5	18.1	10.5
Florida	162.2	144.6	10.3	7.3	12.2	12.7	17.3	6.0	21.2	21.8	20.5	10.1
Georgia	55.9	48.5	4.6	2.8	12.6	13.2	17.4	6.0	20.3	21.3	18.0	10.2
Hawaii	3.5	3.0	0.5	0.1	8.4	9.3	11.1	1.9	18.6	18.6	20.1	10.0
Idaho	4.9	4.1	0.5	0.2	7.8	7.7	16.6	4.1	15.6	16.1	13.3	8.8
Illinois	75.7	66.6	6.0	3.1	12.3	13.3	11.5	5.5	21.8	23.0	15.1	9.8
Indiana	47.1	40.4	3.7	3.0	11.6	12.8	11.4	5.6	19.2	20.4	14.6	8.6
Iowa	12.9	10.8	1.3	0.8	8.7	9.6	9.2	3.9	17.9	18.8	15.0	10.0
Kansas	12.5	11.2	0.6	0.7	9.8	10.1	10.8	6.0	19.0	19.5	16.1	10.6
Kentucky	45.0	37.1	5.8	2.1	12.0	13.3	10.6	5.9	21.5	22.6	17.0	16.5
Louisiana	26.7	22.7	3.2	0.8	10.7	12.0	9.4	3.8	18.4	19.0	16.3	11.7
Maine	7.7	6.7	0.6	0.3	8.5	8.7	9.7	5.4	18.8	19.4	15.2	11.1
Maryland	32.4	28.4	2.7	1.4	11.9	13.2	11.2	4.9	21.0	22.0	16.3	12.4
Massachusetts	41.3	35.6	4.1	1.6	12.5	13.3	14.1	5.2	22.3	23.3	17.5	15.1
Michigan	82.2	71.3	7.4	3.6	11.6	12.7	10.5	5.2	20.6	21.5	17.5	9.5
Minnesota	22.1	19.4	1.6	1.0	11.1	11.7	12.0	5.5	19.4	20.3	15.8	8.3
Mississippi	19.9	17.5	1.2	1.1	11.7	12.2	15.5	6.3	20.2	21.0	18.0	12.9
Missouri	44.2	38.8	3.5	1.9	12.1	12.7	13.2	5.9	20.7	21.3	19.4	9.4
Montana	4.4	3.6	0.5	0.2	9.3	9.3	12.7	5.3	16.8	17.2	14.5	14.3
Nebraska	7.2	6.0	0.6	0.6	9.2	9.5	14.5	5.4	18.0	19.4	12.1	7.3
Nevada	17.6	15.0	1.9	0.7	11.8	12.1	13.4	6.7	21.4	21.8	19.0	20.0
New Hampshire	6.8	5.9	0.5	0.4	9.9	10.5	13.2	5.1	19.0	20.0	15.6	9.8
New Jersey	45.6	40.7	2.7	2.1	11.5	12.7	11.0	4.5	21.1	22.1	14.9	11.0
New Mexico	7.7	6.7	0.9	0.1	10.2	10.4	12.6	3.8	19.0	19.5	15.8	15.4
New York	114.0	93.6	15.7	4.6	11.6	12.7	12.5	4.4	22.0	22.8	20.0	13.6
North Carolina	59.3	51.5	5.1	2.7	11.5	12.0	15.2	5.4	20.0	20.8	19.0	9.1
North Dakota	3.1	2.7	0.2	0.2	9.7	10.4	14.4	4.1	20.4	21.1	19.4	8.6
Ohio	85.5	69.8	9.9	5.7	11.3	12.9	9.7	5.6	19.9	21.5	16.5	8.9
Oklahoma	29.9	26.3	2.3	1.2	12.6	13.1	17.5	5.6	19.8	20.6	17.4	6.5
Oregon	15.8	13.4	2.1	0.3	8.9	9.1	10.2	3.5	17.8	18.4	14.5	10.7
Pennsylvania	75.9	64.1	7.1	4.7	11.5	12.6	11.3	5.6	20.4	21.9	14.3	11.4
Puerto Rico	13.5	6.4	6.7	0.5	8.3	6.0	14.0	5.5	20.5	21.5	18.1	10.5
Rhode Island	5.2	4.7	0.1	0.3	9.1	10.5	4.1	4.4	19.8	21.0	10.6	8.1
South Carolina	26.1	24.0	0.8	1.3	10.8	12.1	5.1	5.2	19.1	19.7	18.9	7.7
South Dakota	4.0	3.7	0.2	0.2	10.6	11.1	14.1	5.1	19.4	19.7	18.2	12.1
Tennessee	46.7	39.5	4.0	3.2	11.8	12.5	15.5	6.1	20.2	21.2	16.0	13.9
Texas	122.0	110.1	6.2	5.7	11.9	12.7	14.4	5.2	20.0	20.6	18.4	10.1
Utah	5.5	4.5	0.6	0.4	8.5	8.8	15.7	4.0	16.6	17.7	12.9	9.2
Vermont	2.7	2.4	0.2	0.1	8.6	8.8	10.6	5.0	19.1	20.6	10.8	4.3
Virginia	40.5	35.5	3.3	1.7	11.5	12.5	12.3	4.3	20.1	21.0	15.6	12.8
Washington	25.9	22.2	2.7	1.0	9.6	10.1	10.5	4.1	18.8	19.9	13.7	10.0
West Virginia	22.0	18.7	2.4	0.8	11.8	12.8	11.3	5.2	22.6	24.1	15.5	12.3
Wisconsin	26.8	23.2	1.8	1.8	10.8	11.4	11.7	6.3	18.1	19.2	14.7	7.1
Wyoming	2.5	2.2	0.1	0.2	9.9	10.2	12.8	7.2	17.4	17.4	14.5	19.2


(continued on next page)

For personal use only. Permission required for all other uses.

Note: Due to data quality limitations, COPD-related acute inpatient hospitalizations and 30-day readmission rates for Medicaid- and commercially-insured individuals in the District of Columbia and Puerto Rico were replaced with the South Atlantic census division values. The 30-day readmission rate for Montana was replaced with the Mountain census division value for commercially-insured individuals.

COPD=chronic obstructive pulmonary disease; MC=Medicare; MD=Medicaid; C=commercial

Figure 6. 30-Day All-Cause Readmission Rates Following COPD-Related Acute Inpatient Hospitalizations by Insurance Type



30-Day All-Cause Readmission Rates Following COPD-Related Acute Inpatient Hospitalizations (%)

Note: Due to data quality limitations, 30-day all-cause readmission rates following COPD-related acute inpatient hospitalizations for Medicaid- and commercially-insured individuals in the District of Columbia and Puerto Rico were replaced with the South Atlantic census division values.

COPD=chronic obstructive pulmonary disease

For personal use only. Permission required for all other uses.

Table 3. COPD-Related Acute Inpatient Hospitalizations for Insured Individuals With COPD as a Percentage of All-Cause, All-Age Acute Inpatient Hospitalizations

Nationwide or State	Prevalence of COPD per 1,000 Insured Individuals	Number of Insured Individuals With COPD (in Thousands)	AHA 2021 Total Acute Inpatient Hospitalizations, All Ages (in Thousands)	COPD-Related Acute Inpatient Hospitalizations for Ages 40 and Older as a % of Total Inpatient Hospitalizations for All Ages
Nationwide	78	11,674	31,967	4.3
Alabama	110	247	601	4.2
Alaska	55	16	50	5.8
Arizona	64	208	644	3.3
Arkansas	99	138	347	4.8
California	56	973	3102	2.9
Colorado	57	142	437	4.3
Connecticut	71	123	365	3.9
Delaware	74	38	98	3.8
District of Columbia	64	19	108	2.8
Florida	97	973	2525	3.4
Georgia	76	330	988	4.1
Hawaii	46	33	105	3.0
Idaho	63	50	132	5.9
Illinois	76	442	1209	4.5
Indiana	97	303	722	6.0
Iowa	78	116	266	6.9
Kansas	79	98	295	4.7
Kentucky	125	274	507	8.2
Louisiana	90	191	534	5.6
Maine	98	72	113	10.0
Maryland	70	193	499	4.8
Massachusetts	67	231	729	3.3
Michigan	104	514	1031	5.7
Minnesota	58	149	500	5.0
Mississippi	101	129	334	5.6
Missouri	98	267	731	5.1
Montana	72	38	94	6.0
Nebraska	71	60	184	4.3
Nevada	81	108	240	5.6
New Hampshire	72	51	117	6.2
New Jersey	67	288	1039	2.1
New Mexico	61	60	177	4.2
New York	71	698	2038	2.8
North Carolina	87	383	984	4.8
North Dakota	75	24	92	4.3
Ohio	97	560	1339	5.8
Oklahoma	109	175	399	6.3
Oregon	67	138	314	6.7
Pennsylvania	75	492	1436	3.5
Puerto Rico	71	130	Not Available ^a	Not Available ^a
Rhode Island	74	42	107	3.1
South Carolina	77	183	512	4.1
South Dakota	74	29	111	3.5
Tennessee	95	295	779	4.3
Texas	72	760	2727	3.4
Utah	44	50	249	2.5
Vermont	68	24	47	8.5
Virginia	69	263	752	4.5
Washington	58	209	520	6.0
West Virginia	143	133	226	8.7
Wisconsin	66	192	472	7.1
Wyoming	81	20	40	7.7

(continued on next page)

For personal use only. Permission required for all other uses.

Note 1: All-cause acute inpatient hospitalization counts were sourced from total facility admissions in the American Hospital Association survey database.³²

Note 2: Due to data quality limitations, COPD-related acute inpatient hospitalizations for Medicaid- and commercially-insured individuals in the District of Columbia were replaced with the South Atlantic census division values.

^aTotal inpatient hospitalizations were not available for Puerto Rico.

COPD=chronic obstructive pulmonary disease

and progressive damage to the lungs over an individual's lifetime.³⁴ Medicaid insured only 9.3% of individuals with COPD despite a COPD prevalence 3 times the commercial rate, in part due to Medicaid insuring the lowest share (10.2%) of individuals.

State also played a role in the distribution of insured individuals, particularly Medicaid. While Medicare and commercial insurance eligibility criteria were generally consistent across states, Medicaid eligibility varied substantially across states that make local decisions (above a minimum threshold) about eligibility for Medicaid coverage. Compared to states that expanded Medicaid coverage prior to 2021, states that had not expanded Medicaid eligibility as of January 1, 2021, (except for Wisconsin) had higher COPD prevalence and lower proportions of individuals aged 40 to 64 who were insured by Medicaid. Future research using interrupted time-series design could analyze whether the more stringent low-income requirements in non-expansion states was related to Medicaid-insured populations being at higher risk of developing COPD.

All-cause mortality rates for individuals with COPD insured by Medicare or Medicaid varied by geography, although Medicare-insured individuals had consistently higher all-cause mortality than those insured by Medicaid. The higher age of the Medicare-insured population compared to the Medicaid-insured population (73 versus 55) likely contributed to this difference. However, within the Medicare-insured COPD population, the relationship between all-cause mortality and age was inconsistent across states. States with Medicare-insured COPD populations older than the national Medicare average did not consistently have higher all-cause mortality rates, nor did states with Medicare-insured COPD populations younger than the national average always have lower all-cause mortality. Of greatest public health concern were the 13 states (West Virginia, Kentucky, the District of Columbia, Mississippi, Oklahoma, Alabama, Maine, Louisiana, Arkansas, Indiana, Ohio, Tennessee, and Georgia) with lower-than-average ages but higher-than-average all-cause mortality rates for the Medicare-insured COPD population, where improved management of COPD and comorbid conditions may have the greatest opportunity to impact mortality. For example, COPD exacerbations may increase the risk of both respiratory and cardiovascular events that can lead to premature death.³⁵ Moreover, states with dual-eligibility at or above the 75th percentile nationally were disproportionately more likely to have lower-than-average Medicare-insured ages but higher-than-average all-cause mortality rates. This finding suggests potential differences in risk factors for COPD

exacerbations and comorbid conditions, including gaps in optimal management of COPD and other medical conditions in low-income Medicare-insured individuals with COPD in these states. This presents an opportunity for research into state-level COPD risk factors and treatment patterns, such as differences in air quality, smoking rates, obesity prevalence, adherence to Global initiative for chronic Obstructive Lung Disease (GOLD) 2024 COPD treatment guidelines,³⁶ and access to specialty care. For example, among individuals with a history of severe COPD exacerbations, GOLD 2024 recommends dual bronchodilator treatment with a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) or triple therapy with LABAs, LAMAs, and inhaled corticosteroids.³⁶ Delays in initiation of triple therapy among individuals with severe COPD exacerbations are associated with an increased risk of exacerbations.³⁷

COPD-related acute inpatient hospitalizations and 30-day all-cause readmissions following hospitalizations also showed variability by state and insurance type. COPD-related acute inpatient hospitalizations ranged from 97 (Idaho) to 200 (District of Columbia) per 1000 insured individuals with COPD, while 30-day all-cause readmission rates ranged from 15.6% (Idaho) to 22.6% (West Virginia). Other research has shown that 55% of readmissions following COPD-related hospitalizations were attributable to non-COPD conditions at the time of return,³⁸ highlighting the importance of timely follow-up and effective care management of COPD and other medical conditions during transition from the hospital to the community when the risk of adverse events is high.³⁹ However, hospitalization and readmission rates alone did not fully represent the burden of COPD on the health care system, as the total number of insured individuals with COPD in each state substantially impacted the absolute number of COPD-related acute inpatient hospitalizations and readmissions. For example, the District of Columbia was among the states with the lowest number of COPD-related acute inpatient hospitalizations nationally despite having the highest hospitalization rate, owing to its smaller number of insured individuals with COPD. In all states except Puerto Rico, Medicare-insured individuals with COPD accounted for the highest share of COPD-related hospitalizations and readmissions. Furthermore, in most states, Medicaid-insured individuals accounted for a higher share of COPD-related hospitalizations and readmissions than commercially-insured individuals, even though Medicaid generally insured a lower percentage of individuals with COPD. This is consistent with research showing higher rates of acute inpatient hospitalizations for most chronic conditions among Medicaid-insured compared to commercially-insured individuals.⁴⁰

This study has several limitations. The analysis used health insurance claims to identify and characterize individuals diagnosed with COPD and quantify COPD-related metrics. Differences and imprecision in coding practices could have resulted in over-identification or under-identification of insured individuals with COPD and COPD-related acute inpatient hospitalizations, and health care access barriers could contribute to under-identification. The study was limited to individuals insured by Medicaid, Medicare, and commercial insurance, excluding those with other insurance types and the uninsured population, which may have disproportionately impacted COPD-related metrics for certain states. Metrics for some states were replaced with regional values due to noncredible sample sizes and/or data quality limitations, and the results for those states could differ from the census division values reported (see Methods section). No adjustments were made for sex, gender, age, or underlying health differences across insurance types and states, so outcomes may reflect differences in population characteristics unrelated to COPD. In addition, information was insufficient to identify individuals who switched between commercial insurance and Medicare or Medicaid in 2021, so some individuals could have been represented in multiple insured populations. Lastly, the effects of the COVID-19 pandemic likely had an impact on the results of this study, including underestimation of COPD prevalence due to fewer opportunities for COPD diagnosis codes to be reported on claims,⁴¹ decreased COPD-related acute inpatient hospitalizations due to public health measures implemented during the COVID pandemic,⁴² and decreased rates of ED/Obs encounters and hospitalizations for minor COPD exacerbations due to patients avoiding the ED and the tightening of criteria for inpatient admission in order to preserve hospital bed capacity.⁴³ In Medicaid, the continuous enrollment provision of the Families First Coronavirus Response Act⁴⁴ also increased membership substantially during this period by maintaining insurance coverage for healthier individuals who may have lost Medicaid coverage in previous years. This would be expected to result in lower observed COPD prevalence and lower rates of COPD-related acute inpatient hospitalizations for individuals insured by Medicaid during this time period compared to the prepandemic period and the period after the unwinding of continuous Medicaid enrollment⁴⁵ following March 2023. Analyses with different time periods, data sources, or methodologies would be expected to have different results.

Health insurance administrative claims are a robust and credible data source that can provide comprehensive information about insured individuals living with COPD. Taken together, the insurance types included in this study

(Medicare, Medicaid, and commercial insurance) provide coverage for 90% of the U.S. population, with the remaining 10% either uninsured or covered under insurance types not included in this study (e.g., Veterans Administration).⁴⁶ COPD is a treatable disease, but gaps in care remain resulting in underdiagnosis, misdiagnosis, and inadequate or inappropriate treatment that can lead to more frequent and more severe exacerbations.³⁷ Understanding the variation in prevalence, demographics, and acute hospital-based utilization of individuals with COPD by state and insurance type provides valuable insights into high-burden areas and population groups with unmet needs. This can be used to develop and refine public health strategies to address these gaps in order to reduce the burden of COPD on individuals and the health care system. Future hypothesis-driven research could expand this understanding by adjusting for underlying differences in the COPD population clinical and demographic characteristics across insurance types and states, allowing statistical comparisons of differences across various populations.

Acknowledgements

Author contributions: All authors contributed to the conception and design of the study, data analysis and interpretation, and drafting and revising the manuscript prior to submission. All authors gave final approval for this version of the manuscript to be published.

The authors would like to thank Amanda McCarthy, Ananya Sridharan, Ifrah Fayyaz, Jared Hirsch, Jaron Jackson, Swad Komanduri, Vivian Chen, and Yen Chung, for their helpful contributions to the analyses, visuals, and supporting materials, as well as Jessica Naber for her review of this manuscript.

Declaration of Interest

CB, MA, SL, and WF are employees of Milliman, Inc., and received consulting fees from AstraZeneca. NF and HG are employees of AstraZeneca Pharmaceuticals LP and hold AstraZeneca stock. DM is a consultant to GlaxoSmithKline, AstraZeneca, Regeneron, Genentech, and the COPD Foundation and receives royalties from Up-to-Date and testifies on behalf of individuals suing the tobacco and vaping industries. The authors report no other conflicts of interest in this work. This study was funded by AstraZeneca Pharmaceuticals LP (Wilmington, Delaware). Milliman, Inc., received consulting fees from AstraZeneca Pharmaceuticals LP to conduct the research and provide editorial support for the manuscript.

References

1. Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. *Am J Respir Crit Care Med*. 2022;206(11):1317-1325. <https://doi.org/10.1164/rccm.202204-0671PP>
2. Centers for Disease Control and Prevention (CDC). About underlying cause of death, 2018-2021, single race. CDC website. Updated November 20, 2023. Accessed August 2024. <http://wonder.cdc.gov/ucd-icd10-expanded.html>
3. Centers for Disease Control and Prevention (CDC). Chronic disease indicators (CDI) data. CDC website. Updated March 17, 2022. Accessed August 2024. <https://nccd.cdc.gov/cdi>
4. Kohansal R, Martinez-Camblor P, Agustí A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. *Am J Respir Crit Care Med*. 2009;180(1):3-10. <https://doi.org/10.1164/rccm.200901-0047OC>
5. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramírez-Sarmiento A, Antó JM, Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. *Eur Respir J*. 2006;27(3):542-546. <https://doi.org/10.1183/09031936.06.00052705>
6. Institute for Health Metrics and Evaluation (IHME). GBD compare. Viz hub health data. IHME website. Published 2021. Accessed August 2024. <https://vizhub.healthdata.org/gbd-compare/>
7. Elonheimo HM, Mattila T, Andersen HR, et al. Environmental substances associated with chronic obstructive pulmonary disease-a scoping review. *Int J Environ Res Public Health*. 2022;19(7):3945. <https://doi.org/10.3390/ijerph19073945>
8. Savitz DA, Woskie SR, Bello A, et al. Deployment to military bases with open burn pits and respiratory and cardiovascular disease. *JAMA Netw Open*. 2024;7(4):e247629. <https://doi.org/10.1001/jamanetworkopen.2024.7629>
9. Thudium RF, Ronit A, Afzal S, et al. Faster lung function decline in people living with HIV despite adequate treatment: a longitudinal matched cohort study. *Thorax*. 2023;78(6):535-542. <https://doi.org/10.1136/thorax-2022-218910>
10. Fan H, Wu F, Liu J, et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Ann Transl Med*. 2021;9(5):390. <https://doi.org/10.21037/atm-20-4576>
11. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. *Chest*. 2004;126(1):59-65. <https://doi.org/10.1378/chest.126.1.59>
12. Mercado N, Ito K, Barnes PJ. Accelerated ageing of the lung in COPD: new concepts. *Thorax*. 2015;70(5):482-489. <https://doi.org/10.1136/thoraxjnl-2014-206084>
13. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. *Lancet*. 2011;378(9795):991-996. [https://doi.org/10.1016/S0140-6736\(11\)60990-2](https://doi.org/10.1016/S0140-6736(11)60990-2)
14. Agency for Healthcare Research and Quality (AHRQ). AHRQ data tools. AHRQ website. Accessed May 16, 2024. <https://datatools.ahrq.gov/hcupnet>
15. Cairns C, Kang K. National hospital ambulatory medical care survey: 2021 emergency department summary tables. Centers for Disease Control and Prevention website. Published 2021. Accessed August 2024. https://www.cdc.gov/nchs/data/nhamcs/web_tables/2021-nhamcs-ed-web-tables-508.pdf
16. Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. *Int J Chron Obstruct Pulmon Dis*. 2020;15:439-460. <https://doi.org/10.2147/COPD.S234942>
17. Keisler-Starkey K, Bunch LN. Health insurance coverage in the United States: 2021. United States Census Bureau website. Published September 2022. Accessed August 2024. <https://www.census.gov/content/dam/Census/library/publications/2022/demo/p60-278.pdf>
18. Social Security Administration (SSA). Medicare. SSA.gov website. Accessed July 31, 2024. <https://www.ssa.gov/pubs/EN-05-10043.pdf>
19. Centers for Medicare and Medicaid Services (CMS). Who enrolls in Medicaid & CHIP? Medicaid.gov website. Published 2021. Accessed August 2024. <https://www.medicaid.gov/state-overviews/score-card/who-enrolls-medicaid-chip/index.html>
20. Hinton E, Raphael J. 10 things to know about Medicaid managed care. Kaiser Family Foundation website. Published March 1, 2023. Accessed August 2024. <https://www.kff.org/medicaid/issue-brief/10-things-to-know-about-medicaid-managed-care/>
21. Kaiser Family Foundation (KFF). Status of state Medicaid expansion decisions: interactive map. KFF website. Updated December 1, 2023. Accessed August 2024. <https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/>
22. Chehal PK, Selvin E, DeVoe JE, Mangione CM, Ali MK. Diabetes and the fragmented state of US health care and policy. *Health Aff (Millwood)*. 2022;41(7):939-946. <https://doi.org/10.1377/hlthaff.2022.00299>
23. Pleasants RA, Rivera MP, Tilley SL, Bhatt SP. Both duration and pack-years of tobacco smoking should be used for clinical practice and research. *Ann Am Thorac Soc*. 2020;17(7):804-806. <https://doi.org/10.1513/AnnalsATS.202002-133VP>
24. Centers for Disease Control and Prevention (CDC). Smoking and tobacco use: adult data. CDC website. Updated May 4, 2023. Accessed August 2024. https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#references

25. Lau CS, Siracuse BL, Chamberlain RS. Readmission after COPD exacerbation scale: determining 30-day readmission risk for COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2017;12:1891-1902. <https://doi.org/10.2147/COPD.S136768>
26. Mapel DW, Dutro MP, Marton JP, Woodruff K, Make B. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. *BMC Health Serv Res*. 2011;11:43. <https://doi.org/10.1186/1472-6963-11-43>
27. Centers for Medicare and Medicaid Services. Medicare monthly enrollment. Data.CMS.gov website. Updated May 31, 2024. Accessed August 2024. <https://data.cms.gov/summary-statistics-on-beneficiary-enrollment/medicare-and-medicaid-reports/medicare-monthly-enrollment/data>
28. United States Census Bureau. American community survey 1-year estimates data profile. United States Census Bureau website. Accessed August 2024. [https://data.census.gov/table?t=Health+Insurance&g=010XX00US\\$0400000&d=ACS+1-Year+Estimates+Data+Profiles](https://data.census.gov/table?t=Health+Insurance&g=010XX00US$0400000&d=ACS+1-Year+Estimates+Data+Profiles)
29. United States Census Bureau. Small area health insurance estimates (SAHIE). United States Census Bureau website. Accessed August 2024. https://www.census.gov/data-tools/demo/sahie/#/?s_measures=ui_snc&s_year=2020
30. Centers for Medicare and Medicaid Services. TAF technical documentation: claims files. CMS website. Published August, 2021. Accessed August 2024. https://resdac.org/sites/datadocumentation.resdac.org/files/2021-08/TAF_TechGuide_Claims_Files.pdf
31. Centers for Medicare and Medicaid Services (CMS). Chronic obstructive pulmonary disease (COPD) readmission updates (ZIP). CMS website. Accessed August 2024. <https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/hospitalqualityinits/downloads/chronic-obstructive-pulmonary-disease-copd-readmission-updates.zip>
32. American Hospital Association (AHA). AHA data hub. AHA Data and Insights website. Updated January 2024. Accessed January 5, 2024. <https://guide.prod.iam.aha.org/stats/states>
33. St Clair P, Gaudette É, Zhao H, Tysinger B, Seyedin R, Goldman DP. Using self-reports or claims to assess disease prevalence: it's complicated. *Med Care*. 2017;55(8):782-788. <https://doi.org/10.1097/MLR.0000000000000753>
34. Agustí A, Melén E, DeMeo DL, Breyer-Kohansal R, Faner R. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. *Lancet Respir Med*. 2022;10(5):512-524. [https://doi.org/10.1016/S2213-2600\(21\)00555-5](https://doi.org/10.1016/S2213-2600(21)00555-5)
35. Singh D, Han MK, Hawkins NM, et al. Implications of cardiopulmonary risk for the management of COPD: a narrative review. *Adv Ther*. 2024;41(6):2151-2167. <https://doi.org/10.1007/s12325-024-02855-4>
36. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2024 report. Published November 2023. Accessed August 2024. <https://goldcopd.org/2024-gold-report/>
37. Evans KA, Pollack M, Portillo E, et al. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: an analysis of the PRIMUS study. *J Manag Care Spec Pharm*. 2022;28(12):1366-1377. <https://doi.org/10.18553/jmcp.2022.28.12.1366>
38. Buhr RG, Jackson NJ, Dubinett SM, Kominski GF, Mangione CM, Ong MK. Factors associated with differential readmission diagnoses following acute exacerbations of chronic obstructive pulmonary disease. *J Hosp Med*. 2020;15(4):219-227. <https://doi.org/10.12788/jhm.3367>
39. Kong CW, Wilkinson TMA. Predicting and preventing hospital readmission for exacerbations of COPD. *ERJ Open Res*. 2020;6(2):00325-2019. <https://doi.org/10.1183/23120541.00325-2019>
40. Gibson TB, Lee TA, Vogeli CS, et al. A four-system comparison of patients with chronic illness: the military health system, Veterans Health Administration, Medicaid, and commercial plans. *Mil Med*. 2009;174(9):936-943. <https://doi.org/10.7205/MILMED-D-03-7808>
41. McGough M, Amin K, Cox C. How has healthcare utilization changed since the pandemic? Peterson-KFF Health System Tracker website. Published January 24, 2023. Accessed January 16, 2024. <https://www.healthsystemtracker.org/chart-collection/how-has-healthcare-utilization-changed-since-the-pandemic/>
42. Tan JY, Conceicao EP, Wee LE, Sim XYJ, Venkatachalam I. COVID-19 public health measures: a reduction in hospital admissions for COPD exacerbations. *Thorax*. 2021;76(5):512-513. <https://doi.org/10.1136/thoraxjnl-2020-216083>
43. Melnick G, O'Leary JF, Zaniello BA, Abrishamian L. COVID-19 driven decline in emergency visits: has it continued, is it permanent, and what does it mean for emergency physicians? *Am J Emerg Med*. 2022;61:64-67. <https://doi.org/10.1016/j.ajem.2022.08.031>
44. United States Department of Labor (DOL). Families first coronavirus response act: employee paid leave rights. Published 2020. Accessed January 16, 2024. https://www.dol.gov/sites/dolgov/files/WHd/pandemic/ffca-employee_paid_leave_rights.pdf
45. Centers for Medicare and Medicaid Services. Archived: Unwinding and returning to regular operations after COVID-19. Medicaid.gov website. Accessed June 4, 2024. <https://www.medicaid.gov/resources-for-states/coronavirus-disease-2019-covid-19/unwinding-and-returning-regular-operations-after-covid-19/index.html>
46. Kaiser Family Foundation (KFF). Health insurance coverage of the total population. KFF website. Updated 2024. Accessed August 2024. <https://www.kff.org/other/state-indicator/total-population/>